Evaluation of the efficacy of memantine in the treatment of fibromyalgia: study protocol for a doubled-blind randomized controlled trial with six-month follow-up

Trials

Javier Garcia-Campayo¹  Miquel Roca²  Rosa Magallon⁵  Yolanda López-del-Hoyo³  Eva Andrés⁴  Raquel Arcega³  Mari-Cruz Pérez-Yus³  Bárbara Masluk³  Marta Puebla³  Bárbara Olivan-Blázquez³ 

[1] Department of Psychiatry, Miguel Servet Hosìal, Avda Isabel La Catolica 1, 50.009, Zaragoza, Spain;Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), University of Balearic Islands, Palma de Mallorca, Spain;Red de Actividades Preventivas y de Promoción de la Salud (REDIAPP) (RD06/0018), Instituto Aragonés de Ciencias de la Salud (IACS), Aragón, Spain;Unidad Epidemiología Clínica, Hospital 12 de Octubre, CIBER Epidemiología y Salud Pública, Madrid, Spain;Centro de Salud Arrabal, Zaragoza, Spain

关键词: Randomized controlled trial;    Magnetic resonance spectroscopy;    Chronic pain;    Memantine;    Fibromyalgia;   

Others  :  1095011
DOI  :  10.1186/1745-6215-14-3

 received in 2012-08-07, accepted in 2012-12-18,  发布年份 2013

【 摘 要 】

Background

Fibromyalgia is a prevalent chronic rheumatic disease of great clinical importance. Recent studies have found raised levels of glutamate in the insula, hippocampus and posterior cingulate cortex regions of the brains of fibromyalgia (FM) patients. This finding has led researchers to speculate about the usefulness of glutamate-blocking drugs such as memantine in the treatment of fibromyalgia. The hypothesis of this study is that the administration of memantine will reduce the glutamate levels, and futhermore, will decrease the perceived pain. The aim of this study is to evaluate the efficacy of memantine in the treatment of pain (pain perception). A secondary objective is to evaluate the efficacy of memantine in the treatment of other clinical symptoms of FM, and to evaluate the efficacy of memantine in reducing brain levels of glutamate, and its effects on the central nervous system as a whole.

Method/Design

A double-blind parallel randomized controlled trial. Participants, Seventy patients diagnosed with FM will be recruited from primary health care centers in Zaragoza, Spain. Intervention. The subjects will be randomized in two groups: A) A treatment group (n = 35), which will receive 20 mg of memantine daily; B) A control group (n = 35), to which will be administered a placebo. There will be a six-month follow-up period (including a titration period of one month). Outcomes. The main efficacy variable of this study is pain (pain perception). The secondary efficacy variables are clinical symptoms (pain threshold, cognitive function, health status, anxiety, depression, clinical impression and quality of life) and glutamate levels in different regions of the brain, which will be assessed by magnetic resonance spectroscopy. Randomization and blinding. Randomization has been computer-generated, and the random allocation sequence will be implemented by telephone. Subjects of the study and the research assistants will be blinded to group assignment.

Discussion

There is a need for the development of innovative and more effective treatments for fibromyalgia. This clinical trial will determine whether memantine can be an effective pharmacological treatment for fibromyalgia patients.

Trial registration

Current Controlled Trialshttp://ISRCTN45127327 webcite EUDRACT 2011-006244-73

【 授权许可】

   
2013 Olivan-Blázquez et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Wolfe F, Smythe HA, Yunus MB, Bennet RM, Bombardier C, Goldenberg ADL: American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthr Rheum 1990, 33:160-172.
• [2]Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M: Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010, 39:448-453.
• [3]Gamero Ruiz F, Gabriel Sánchez R, Carbonell Abelló J, Tornero Molina J, Sanchez-Magro I: Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 2005, 205:157-163.
• [4]Garcia Campayo J, Magdalena J, Fernández E, Magallón R, Salas M, Sobradiel N: Effectiveness of treatments for fibromyalgia depending of level of care: a meta-analysis. Arthitis Res Ther 2008, 10:R81. BioMed Central Full Text
• [5]Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, Stewart KE, Alarcon GS, Mountz JD: Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus are associated with low pain threshold levels. Arthr Rheum 1995, 38:926-938.
• [6]Kwiatek R, Barnden L, Tedman R, Jarret R, Chew J, Rowe C, Pile K: Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the thalami. Arthr Rheum 2000, 43:2823-2833.
• [7]García-Campayo J, Sanz-Carrillo C, Baringo T, Ceballos C: SPECT scan in somatization disorder patients. Australia & NZ J Psychiatry 2001, 35:359-363.
• [8]Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ: Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009, 60:3146-3152.
• [9]Valdés M, Collado A, Bargalló N, Vázquez M, Rami L, Gómez E, Salamero M: Increased glutamate/glutamine compounds in the brains of patients with fibromyalgia: a magnetic resonance spectroscopy study. Arthritis Rheum 2010, 62:1829-1836.
• [10]Fayed N, Garcia-Campayo J, Magallón R, Andrés-Bergareche H, Luciano JV, Andres E, Beltrán J: Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 2010, 12:R134. BioMed Central Full Text
• [11]Harris RE: Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther 2010, 12:141. BioMed Central Full Text
• [12]Choi DW, Koh JY, Petres S: Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neuroscience 1988, 8:185-196.
• [13]Johnson JW, Kotermanski SE: Mechanism of action of memantine. Curr Opin Pharmacology 2006, 6:61-67.
• [14]Staud R, Vierck CJ, Robinson ME, Price DD: Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain 2005, 6:323-332.
• [15]Weinbroum AA, Rudick V, Paret G, Ben-Abraham R: The role of dextromethorphan in pain control. Can J Anaesth 2000, 47:585-596.
• [16]Graven-Nielsen T, Aspegren-Kendall S, Henriksson KG, Bengtsson M, Sörensen J, Johnson A, Gerdle B, Arendt-Nielsen L: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483-491.
• [17]Alviar MJ, Hale T, Dungca M: Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev 2011, 7(12):CD006380.
• [18]Chen HSV, Lipton SA: The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006, 97:1611-1626.
• [19]Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333-1341.
• [20]Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I and Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324.
• [21]Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ: A 24-week open-label extension of memantine in moderate to severe Alzheimer’s disease. Arch Neurol 2006, 63:49-54.
• [22]Park JW, Suh GI, Shin HE, Park GE: Influence of memantine on nociceptive responses of the trigeminocervical complex after formalin injection. Cephalalgia 2012, 32(4):308-316.
• [23]Suzuki M: Role of N-methyl-D-aspartate receptor antagonists in postoperative pain management. Curr Opin Anaesthesiol 2009, 22(5):618-622.
• [24]Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S: Memantine in the preventive treatment of refractory migraine. Headache 2008, 48(9):1337-1342.
• [25]Recla JM, Sarantopoulos CD: Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy? Med Hypotheses 2009, 73(2):177-183.
• [26]Nikolajsen L, Gottrup H, Kristensen AGD, Jensen TS: Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000, 91:960-966.
• [27]Sinis N, Birbaumer N, Gustin S, Schwarz A, Bredanger S, Becker ST, Unertl K, Schaller HE, Haerle M: Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 2007, 23:237-243.
• [28]Hackworth RJ, Tokarz KA, Fowler IM, Wallace SC, Stedje-Larsen ET: Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain. Anesth Analg 2008, 107:1377-1379.
• [29]Staud R: Drugs to treat fibromyalgia - the transatlantic difference. Curr Opin Investig Drugs 2010, 11:16-18.
• [30]Vargas A, Vargas A, Hernández-Paz R, Sánchez-Huerta JM, Romero-Ramírez R, Amezcua-Guerra L, Kooh M, Nava A, Pineda C, Rodríguez-Leal G, Martínez-Lavín M: Sphygmomanometry-evoked allodynia – a simple bedside test indicative of fibromyalgia: a multicenter developmental study. J Clin Rheumatol 2006, 12:272-274.
• [31]Sriwatanakul K, Kelvie W, Lasagna L: Studies with different types of visual analog scales for measurement of pain. Clin Phrmacol Ther 1983, 34:234-239.
• [32]Lobo A, Saz P, Marcos G, Día JL, de la Cámara C, Ventura T, Morales Asín F, Fernando Pascual L, Montañés JA, Aznar S: Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc) 1999, 112:767-774.
• [33]Rivera J, Gonzalez T: The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004, 22:554-560.
• [34]Tejero A, Guimerá EM, Farré JM, Peri JM: Uso clíınico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. Rev Dep Psiquiatr Fac Med Barc 1986, 13:233-238.
• [35]Badía X, Roset M, Herdman Mand Segura A: La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc) 1999, 112(Suppl 1):79-86.
• [36]Glass JM: Fibromyalgia and cognition. J Clin Psychiatry 2008, 69(Suppl 2):20-24.
• [37]Suhr JA: Neuropsychological impairment in fibromyalgia: relation to depression, fatigue, and pain. J Psychosom Res 2003, 55:321-329.
• [38]Luerding R, Weigand T, Bogdahn U, Schmidt-Wilcke T: Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: structural correlates of pain-cognition interaction. Brain 2008, 131(12):3222-3231.
• [39]Aguglia A, Salvi V, Maina G, Rossetto I, Aguglia E: Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates. J Affect Disord 2011, 128:262-266.
• [40]Owen RT: Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today (Barc) 2012, 48:469-478.
• [41]Glodzik L, King KG, Gonen O, Liu S, De Santi S, de Leon MJ: Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1005-1012.
• [42]Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM: Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005, 162:394-396.
• [43]Pioro EP, Majors A, Mitsumoto H, Nelson DR, Ng T: 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurol 1999, 53:71-79.
• [44]Reynolds NC, Prost RW, Mark LP: Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005, 1031:82-89.